
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase 3 CROWN Study

April 2025

EM-DEU-lor-0119





### CROWN: Subsequent Treatment and PFS2 (WCLC 2024)



	5-Year Analysis					
Planned Interim Analysis Efficacy Safety Expanded Safety Dose Genomic   Analysis Analysis Analysis Analysis Analysis Modifications Analysis		Summary				

# Clinical and molecular characteristics of early progressors (≤12 months) on lorlatinib vs those who remained progression free after 5 years

Clinical Characteristics	Early progressors (n=28) <sup>a</sup>	(n=45) <sup>a</sup>	Total (n=73)	Molecular profiling, n (%) <sup>c</sup>	Early progressors	Nonprogressors (n=45)ª
Age, mean (SD), years	60.5 (12.9)	56.1 (14.0)	57.8 (13.7)		(n=28)ª	(11-40)
Sex, n (%)				Confirmed ALK positive	14 (50)	35 (78)
Male	16 (57)	24 (53)	40 (55)	EML4-ALK variant 1	6 (21)	10 (22)
Female	12 (43)	21 (47)	33 (45)	EML4-ALK variant 2	0	5 (11)
Race, n (%) <sup>b</sup>				EML4-ALK variant 3	5 (18)	11 (24)
Asian	15 (54)	28 (62)	43 (59)	EML4-ALK other variant	3 (11)	7 (16)
White	12 (43)	16 (36)	28 (38)	Other ALK fusion	0	2 (4)
ECOG performance status, n (%)				Unconfirmed <i>ALK</i> positive <sup>d</sup>	14 (50)	10 (22)
0	11 (39)	23 (51)	34 (47)	TP53 mutation detected	16 (57)	10 (22)
1	15 (54)	22 (49)	37 (51)			
2	2 (7)	0	2 (3)			
Brain metastases at baseline, n (%)						
Yes	6 (21)	10 (22)	16 (22)			
No	22 (79)	35 (78)	57 (78)			
Tumor burden at baseline, mm			NA			
Mean (SD)	84.9 (45.7)	54.7 (34.4)	NA			

<sup>a</sup>Early progressors are defined as patients with PFS events (PD or death) within 12 months of the start of the study. Nonprogressors are defined as patients who were PFS-free (alive with no documented PD) at 60 months (including patients with PFS events >60 months). <sup>b</sup>There was 1 (4%) patient in the early progressors group and 1 (2%) patient in the nonprogressors group with other or missing race. <sup>c</sup>Based on ctDNA analysis at baseline and/or tumor tissue at screening. Only based on ctDNA analysis for patients in China. <sup>d</sup>ctDNA was either NA, not tested, or tested with no ctDNA detected. Tumor tissue was either NA or testing had failed.




Mok. TSK, et al. Presented at: WCLC Annual Meeting; September 7-10th, 2024; San Diego, CA.



Subsequent systemic anticancer therapy

- After 5 years of follow-up, 75 of 149 (50%) patients had discontinued lorlatinib and 135 of 142 (95%) had discontinued crizotinib<sup>a</sup>
- 38 of 149 (26%) patients in the lorlatinib arm and 109 of 147 (74%) in the crizotinib arm had ≥1 subsequent systemic anticancer therapy



~	Planned Interim	5-Year Analysis						
1 Overview	Analysis	Efficacy Analysis	Safety Analysis	Expanded Safety (WCLC 2024)	Dose Modifications	Genomic Analysis	Subsequent Tx and PFS2 (WCLC 2024)	Summary

#### Details of first subsequent systemic anticancer therapy


	Lorlatinib (n=38)	Crizotinib (n=109)
First subsequent systemic anticancer therapy, n (%)		
ALK TKI	23 (61)	101 (93)
Alectinib	12 (52)	68 (67)
Crizotinib	4 (17)	5 (5)
Ceritinib	3 (13)	3 (3)
Lorlatinib	3 (13)	4 (4)
Brigatinib	1 (4)	21 (21)
Chemotherapy ± anti-angiogenic	13 (34)	4 (4)
Chemotherapy/immunotherapy	1 (3)	0
Chemotherapy/immunotherapy/anti-angiogenic	1 (3)	0
Other <sup>a</sup>	0	4 (4)
OT on first subsequent systemic anticancer therapy, median (IQR), months	9.3 (2.6-22.6)	14.9 (5.3-38.4)
ALK TKIs as first subsequent therapy <sup>b</sup>	12.5 (2.0-31.7)	15.8 (7.0-39.9)
Non–ALK TKIs as first subsequent therapy <sup>c</sup>	6.7 (2.6-19.7)	1.2 (0.8-2.7)



<sup>a</sup>Includes investigational drug, cabozantinib, and osimertinib. <sup>b</sup>N numbers are 23 for lorlatinib and 101 for crizotinib. <sup>c</sup>N numbers are 15 for lorlatinib and 8 for crizotinib. ALK, anaplastic lymphoma kinase; DOT, duration of treatment; IQR, interquartile range; TKI, tyrosine kinase inhibitor. Mok. TSK, et al. Presented at: WCLC Annual Meeting; September 7-10th, 2024; San Diego, CA.



#### Duration of treatment for subsequent therapies post lorlatinib



Discontinued due to AE or other reasons PR ົດ 2 TKI PR Ł PR PR PR Ë <sup>0</sup>Chemo CR

 ALK TKIs and chemo were used as subsequent lines of treatment in patients who discontinued lorlatinib due to PD or other reasons

36

Duration of treatment, months

42

54

66

60

72

30

Outcomes of subsequent treatment varied, and responses were observed in patients irrespective of prior Iorlatinib DOT or response



AE, adverse event; ALK, anaplastic lymphoma kinase; chemo, chemotherapy; CR, complete response; DOT, duration of treatment; Immuno, immunotherapy; INV PD, investigator-determined progressive disease; PD, progressive disease based on the follow-up anticancer therapy case report form; PR, partial response; TKI, tyrosine kinase inhibitor. Mok. TSK, et al. Presented at: WCLC Annual Meeting; September 7-10th, 2024; San Diego, CA.

Ĩ

12


18

24

6

Planned Interim AnalysisEfficacySafetyExpanded SafetyDoseGenomicSubsequent Tx and PFSAnalysisAnalysisAnalysis(WCLC 2024)ModificationsAnalysis(WCLC 2024)	2 Summary

# PFS2 was longer in patients who received lorlatinib vs crizotinib as the study treatment



	Lorlatinib (N=149)	Crizotinib (N=147)	
Duration of follow-up for PFS2, median (95% CI), months	61.4 (59.2-62.5)	58.4 (56.8-61.9)	
PFS2 events, n (%)	48 (32)	78 (53)	
PFS2, median (95% CI), months	NR (NR-NR)	37.9 (27.4-50.1)	
HR (95% CI)	0.43 (0.30-0.62)		



CI, confidence interval; HR, hazard ratio; NR, not reached; PFS2, time from randomization to the date of disease progression with first subsequent systemic anticancer therapy or death. Mok. TSK, et al. Presented at: WCLC Annual Meeting; September 7-10th, 2024; San Diego, CA.